Pharmacogenetics for Pain Management in Joint Replacement Patients

NCT ID: NCT03772535

Last Updated: 2021-02-12

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE3

Total Enrollment

50 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-12-03

Study Completion Date

2021-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to determine the ability to use pharmacogenetic testing in a joint replacement practice to prescribe the most effective pain medicine for a specific patient.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Arthroplasty Complications

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

SCREENING

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Control Group

Subjects in this arm will receive the standard postoperative pain prescription protocol.

Group Type NO_INTERVENTION

No interventions assigned to this group

Pharmacogenomics Guided Group

Subjects in this group will receive postoperative pain prescriptions based on the results of pharmacogenomic testing.

Group Type ACTIVE_COMPARATOR

Pharmacogenomics Testing

Intervention Type DIAGNOSTIC_TEST

The doctor will use genetic test results to prescribe medications that are a most effective for subject.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Pharmacogenomics Testing

The doctor will use genetic test results to prescribe medications that are a most effective for subject.

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Primary total hip or total knee arthroplasty cases

Exclusion Criteria

* History of narcotic dependence
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Anderson Orthopaedic Research Institute

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

William Hamilton, MD

Role: PRINCIPAL_INVESTIGATOR

Anderson Orthopaedic Research Institute

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Anderson Orthopaedic Research Institute

Alexandria, Virginia, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

AORI 2018-0100

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

ACL-R Opioid Sparing Study
NCT06561035 ENROLLING_BY_INVITATION PHASE3